Found: 5
Select item for more details and to access through your institution.
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 4, p. 565, doi. 10.1007/s40262-021-01078-y
- By:
- Publication type:
- Article
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 825, doi. 10.1007/s00280-022-04417-3
- By:
- Publication type:
- Article
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [<sup>14</sup>C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article